Roche's Risdiplam Data Stir Up SMA Market

Positive results for the Swiss major's oral therapy suggests that Biogen and Ionis' monopoly of the lucrative spinal muscular atrophy market with Spinraza could soon be under considerable threat.

Hands
Helping hand for babies with rare genetic disease • Source: Shutterstock

A few weeks after stopping the development of its spinal muscular atrophy (SMA) candidate olesoxime, Roche has presented successful data from a trial of risdiplam, now its most advanced compound to tackle a disorder that is the leading genetic cause of mortality in infants and toddlers.

The Swiss major and partners PTC Therapeutics Inc. and the SMA Foundation in the US have presented an update...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip